A straightforward guide to the basic science behind arrhythmogenesis

Heart

Volumn 100, Issue 24, 2014, Pages 1907-1915

  Dumotier, Berengere M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL CAV1.2; CALCIUM CHANNEL L TYPE; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; SODIUM CHANNEL;

ACTION POTENTIAL DURATION; ARRHYTHMOGENESIS; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; DELAYED AFTERDEPOLARIZATION; EARLY AFTERDEPOLARIZATION; EXCITATION CONTRACTION COUPLING; EXTRASYSTOLE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART AUTOMATICITY; HEART CONDUCTION; HEART DEPOLARIZATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SICK SINUS SYNDROME; SINUS NODE; SODIUM CURRENT; SUPRAVENTRICULAR TACHYCARDIA; T WAVE; ACTION POTENTIAL; ARRHYTHMIAS, CARDIAC; DIASTOLE; HEART MUSCLE CONDUCTION SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM CHANNELS; DIASTOLE; HEART CONDUCTION SYSTEM; HUMANS; SODIUM CHANNELS;

EID: 84922481934     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305647     Document Type: Review

References (36)

1. Bers DM, Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J Pharmacol Sci 2006;100:315-22.
2. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
3. Furutani M, Trudeau MC, Hagiwara N, et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 1999;99:2290-4.
4. Peterson LB, Eskew JD, Vielhauer GA, et al. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Mol Pharm 2012;9:1841-6.
5. Antzelevitch C, Nesterenko V, Shryock JC, et al. The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol 2014;221:137-68.
6. Varró A, Baczkó I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol 2011;164:14-36.
7. Hlaing T, DiMino T, Kowey PR, et al. ECG repolarization waves: their genesis and clinical implications. Ann Noninvasive Electrocardiol 2005;10:211-23.
8. Savelieva I, Yap YG, Yi G, et al. Comparative reproducibility of QT, QT peak, and T peak-T end intervals and dispersion in normal subjects, patients with myocardial infarction, and patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998;21(11 Pt 2):2376-81.
9. Puisieux FL, Adamantidis MM, Dumotier BM, et al. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996;117:1377-9.
10. Darpo B, Sarapa N, Garnett C, et al. The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?" Ann Noninvasive Electrocardiol 2014;19:70-81.
11. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
12. Guérard N, Jordaan P, Dumotier B. Analysis of Unipolar Electrograms in Rabbit Heart Demonstrated the Key Role of Ventricular Apicobasal Dispersion in Arrhythmogenicity. Cardiovasc Toxicol Published Online First: April 2014. doi: 10.1007/s12012-014-9254-2
13. Jacobson I, Carlsson L, Duker G. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. J Pharmacol Toxicol Methods 2011;63:40-6.
14. Gintant GA. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 2008;119:199-209.
15. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 2011;108:871-83.
16. Pogwizd SM, Schlotthauer K, Li L, et al. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001;88:1159-67.
17. Driessen HE, Bourgonje VJ, van Veen TA, et al. New antiarrhythmic targets to control intracellular calcium handling. Neth Heart J 2014;22:198-213.
18. Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 2012;125:2059-70.
19. Oros A, Houtman MJ, Neco P, et al. Robust anti-arrhythmic effi cacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. Br J Pharmacol 2010;161:162-75.
20. Sager PT, Gintant G, Turner JR, et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 2014;167:292-300.
21. Acimovic I, Vilotic A, Pesl M, et al. Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools. Biomed Res Int 2014;2014:512831.
22. DiFrancesco D. The pacemaker current (I(f)) plays an important role in regulating SA node pacemaker activity. Cardiovasc Res 1995;30:307-8.
23. Stern MD, Maltseva LA, Juhaszova M, et al. Hierarchical clustering of ryanodine receptors enables emergence of a calcium clock in sinoatrial node cells. J Gen Physiol 2014;143:577-604.
24. Ferrari R. Ivabradine: Heart Rate and Left Ventricular Function. Cardiology 2014;128:226-30.
25. King JH, Huang C, Fraser JA. Determinants of myocardial conduction velocity: implications for arrhythmogenesis. Front Physiol 2013;4:154.
26. van Hoorn F, Campian ME, Spijkerboer A, et al. SCN5A mutations in Brugada syndrome are associated with increased cardiac dimensions and reduced contractility. PLoS One 2012;7:e42037.
27. Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 2014;114:1483-99.
28. Pandit SV, Jalife J. Rotors and the dynamics of cardiac fibrillation. Circ Res 2013;112:849-62.
29. Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008;45:32-43.
30. Nattel S, Guasch E, Savelieva I, et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014;35:1448-56.
31. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005;85:1205-53.
32. Maltsev VA, Lakatta EG. Dynamic interactions of an intracellular Ca2+ clock and membrane ion channel clock underlie robust initiation and regulation of cardiac pacemaker function. Cardiovasc Res 2008;77:274-84.
33. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.
34. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias. Circulation 2003;108:1871-909.
35. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2006;114:e385-484.
36. Priori S, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013;15:1389-406.